Dihydropyridine calcium channel blocker; activity resides mainly in the ()-isomer. Prepn: S. F. Campbell et al., EP 89167; eidem, US 4572909 (1983, 1986 both to Pfizer). Synthesis and pharmacology of racemate and enantiomers: J. E. Arrowsmith et al., J. Med. Chem. 29, 1696 (1986). Calcium antagonist activity: R. A. Burges et al., J. Cardiovasc. Pharmacol. 9, 110 (1987). GC determn in plasma: A. P. Beresford et al., J. Chromatogr. 420, 178 (1987). Metabolism: idem et al., Xenobiotica 18, 245 (1988). Review of pharmacology and therapeutic efficacy: M. Haria, A. J. Wagstaff, Drugs 50, 560-586 (1995). Clinical potential in severe heart failure: M. Packer et al., N. Engl. J. Med. 335, 1107 (1996). Review of mechanism of plaque stabilization: R. P. Mason, Atherosclerosis 165, 191-199 (2002); of clinical potential in combination with atorvastatin in atherosclerosis: J. W. Jukema, J. W. A. van der Hoorn, Expert Opin. Pharmacother. 5, 459-468 (2004).
Antianginal; antihypertensive.
Antianginal; Antihypertensive; Dihydropyridine Derivatives; Calcium Channel Blocker; Dihydropyridine Derivatives